|
gptkbp:instanceOf
|
gptkb:public_company
|
|
gptkbp:alsoKnownAs
|
gptkb:F._Hoffmann-La_Roche_AG
|
|
gptkbp:CEO
|
gptkb:Thomas_Schinecker
|
|
gptkbp:chairman
|
gptkb:Christoph_Franz
|
|
gptkbp:competitor
|
gptkb:Bayer
gptkb:Pfizer
gptkb:AstraZeneca
gptkb:Johnson_&_Johnson
gptkb:Merck_&_Co.
gptkb:Sanofi
gptkb:AbbVie
gptkb:Amgen
gptkb:Novartis
GlaxoSmithKline
|
|
gptkbp:country
|
gptkb:Switzerland
|
|
gptkbp:division
|
Pharmaceuticals
Diagnostics
|
|
gptkbp:environmentalImpact
|
committed to sustainability
|
|
gptkbp:focusArea
|
immunology
infectious diseases
neuroscience
oncology
ophthalmology
|
|
gptkbp:founded
|
1896
|
|
gptkbp:founder
|
gptkb:Fritz_Hoffmann-La_Roche
|
|
gptkbp:headquartersLocation
|
gptkb:Basel,_Switzerland
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Roche Holding
|
|
gptkbp:industry
|
pharmaceuticals
diagnostics
|
|
gptkbp:ISIN
|
CH0012032048
|
|
gptkbp:listedOn
|
gptkb:SIX_Swiss_Exchange
|
|
gptkbp:marketCap
|
over CHF 200 billion (2023)
|
|
gptkbp:memberOf
|
gptkb:International_Federation_of_Pharmaceutical_Manufacturers_&_Associations
gptkb:European_Federation_of_Pharmaceutical_Industries_and_Associations
|
|
gptkbp:netIncome
|
CHF 13.5 billion (2023)
|
|
gptkbp:notableAcquisition
|
gptkb:Foundation_Medicine_(2018)
gptkb:Genentech_(2009)
Flatiron Health (2018)
Spark Therapeutics (2019)
Chugai Pharmaceutical (majority stake)
GenMark Diagnostics (2021)
Inflazome (2020)
Stratos Genomics (2020)
TIB Molbiol (2021)
|
|
gptkbp:numberOfEmployees
|
over 100,000
|
|
gptkbp:parentCompany
|
gptkb:Roche_Group
|
|
gptkbp:product
|
gptkb:Saizen
gptkb:RoActemra
gptkb:Venclexta
gptkb:Actemra
gptkb:Alecensa
gptkb:Avastin
gptkb:Bactrim
gptkb:Bonviva
gptkb:Cellcept
gptkb:Cotellic
gptkb:Erivedge
gptkb:Esbriet
gptkb:Fuzeon
gptkb:Gazyva
gptkb:Hemlibra
gptkb:Herceptin
gptkb:Kadcyla
gptkb:MabThera
gptkb:Madopar
gptkb:Ocrevus
gptkb:Pegasys
gptkb:Perjeta
gptkb:Polivy
gptkb:Rituxan
gptkb:Rocephin
gptkb:Rozlytrek
gptkb:Tamiflu
gptkb:Tarceva
gptkb:Tecentriq
gptkb:Valium
gptkb:Xeloda
gptkb:Xenical
gptkb:Zelboraf
Neorecormon
|
|
gptkbp:rank
|
gptkb:Forbes_Global_2000
gptkb:Fortune_Global_500
|
|
gptkbp:revenue
|
CHF 63.3 billion (2023)
|
|
gptkbp:slogan
|
Doing now what patients need next
|
|
gptkbp:stockExchange
|
gptkb:SIX_Swiss_Exchange
|
|
gptkbp:stockSymbol
|
gptkb:ROG
|
|
gptkbp:subsidiary
|
gptkb:Genentech
gptkb:Chugai_Pharmaceutical
gptkb:Ventana_Medical_Systems
|
|
gptkbp:website
|
https://www.roche.com
|
|
gptkbp:主要株主
|
gptkb:Roche_family
Novartis (until 2021)
|
|
gptkbp:bfsParent
|
gptkb:Bernard_Poussot
|
|
gptkbp:bfsLayer
|
6
|